Organization
School of Medicine Department of Medical Oncology Lecturer
Title
Lecturer
External link
HIRAKAWA Masahiro
Research Projects
-
Analysis of 5-FU resistance in colon cancer using BH3 profiling
Grant number：17K07200 2017.4 - 2020.3
Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
KAWANO Yutaka
Grant amount：\4810000 （ Direct Cost: \3700000 、 Indirect Cost：\1110000 ）
BH3 profiling identified BCLXL protein as a functional role for 5-FU resistance in colon cancer cell lines. Knockdown of BCLXL protein recovered the sensitivity to 5-FU in 5-FU resistant colon cancer cells. Furthermore, mice study showed that BCLXL inhibitor could both control tumor growth and cause apoptosis in 5-FU resistant colon cancer cells. In summary, BCLXL inhibitor is thought to be one of the promising drug for 5-FU resistant colon cancer.
-
A novel approach in the treatment of metastatic gastric cancer: targeting the STn synthase
Grant number：24590921 2012.4 - 2015.3
Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
SATO Yasushi, TAKIMOTO Risyu, KATO Jyunji, HIRAKAWA Masahiro
Grant amount：\5330000 （ Direct Cost: \4100000 、 Indirect Cost：\1230000 ）
ST6GalNAc I is a sialyltransferase controlling the expression of sialyl-Tn antigen (STn), which is overexpressed in several epithelial cancers, including gastric cancer, and is highly correlated with cancer metastasis. However, the functional contribution of ST6GalNAc I to development or progression of gastric cancer remains unclear. We investigated the effects of suppression of ST6GalNAc I on gastric cancer in vitro and in vivo. ST6GalNAc I siRNA inhibited gastric cancer cell growth, migration, and invasion in vitro. Furthermore, intraperitoneal administration of ST6GalNAc I siRNA- liposome significantly inhibited peritoneal dissemination and prolonged the survival of xenograft model mice with peritoneal dissemination of gastric cancer. Therefore, ST6GalNAc I may be a potential target for treatment of metastasizing gastric cancer.